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Abstract
Background: Recent directions in the treatment of ADHD have involved both a broadening of
pharmacological perspectives to include nor-adrenergic as well as dopaminergic agents. A review
of animal and human studies of pharmacological and therapeutic directions in ADHD suggests that
the D1 receptor is a specific site for dopaminergic regulation of the PFC, but optimal levels of
dopamine (DA) are required for beneficial effects on working memory. Animal and human studies
indicate that the alpha-2A receptor is also important for prefrontal regulation, leaving open the
question of the relative importance of these receptor sites. The therapeutic effects of ADHD
medications in the prefrontal cortex have focused attention on the development of working
memory capacity in ADHD.
Hypothesis: The actions of dopaminergic vs noradrenergic agents, currently available for the
treatment of ADHD have overlapping, but different actions in the prefrontal cortex (PFC) and
subcortical centers. While stimulants act on D1 receptors in the dorsolateral prefrontal cortex,
they also have effects on D2 receptors in the corpus striatum and may also have serotonergic
effects at orbitofrontal areas. At therapeutic levels, dopamine (DA) stimulation (through DAT
transporter inhibition) decreases noise level acting on subcortical D2 receptors, while NE
stimulation (through alpha-2A agonists) increases signal by acting preferentially in the PFC possibly
on DAD1 receptors. On the other hand, alpha-2A noradrenergic transmission is more limited to
the prefrontal cortex (PFC), and thus less likely to have motor or stereotypic side effects, while
alpha-2B and alpha-2C agonists may have wider cortical effects. The data suggest a possible
hierarchy of specificity in the current medications used in the treatment of ADHD, with guanfacine
likely to be most specific for the treatment of prefrontal attentional and working memory deficits.
Stimulants may have broader effects on both vigilance and motor impulsivity, depending on dose
levels, while atomoxetine may have effects on attention, anxiety, social affect, and sedation via
noradrenergic transmission.
Tests of the hypothesis: At a theoretical level, the advent of possible specific alpha-2A
noradrenergic therapies has posed the question of the role of working memory in ADHD. Head
to head comparisons of stimulant and noradrenergic alpha-2A, alpha-2B and alpha-2C agonists,
utilizing vigilance and affective measures should help to clarify pharmacological and therapeutic
differences.
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Background
Recent directions in the treatment of ADHD have
involved both a broadening of pharmacological perspec-
tives to include nor-adrenergic as well as dopaminergic
agents. This offers an opportunity, in conjunction with
animal studies for a better understanding of the differen-
tial selectivity of these agents in the treatment of ADHD.
A number of theories have been proposed for the effect of
CNS stimulants on dopaminergic (DA) transmission in
ADHD.
Theories of cognitive processing
Moghaddam and Homayoun [1] have described two dis-
tinct patterns of cerebral cognitive processing. A modular
view is supported by animal and neurophysiological find-
ings [2-4]. A second connectionist view emphasizes paral-
lel distributed neural networks [5-7]. Contemporary
approaches consider both types of processing relevant and
generally assume that modular processing is a modifica-
tion of parallel computational networks. The dorsolateral
PFC (dlPFC) receives extensive innervations from the
mediodorsal nucleus of the thalamus and sends promi-
nent projections to dorsal striatum, nucleus accumbens
and ventral tegmental area, allowing a key role in execu-
tive functions. On the other hand the orbitofrontal cortex
(OFC) receives inputs from sensory associative cortices,
particularly olfactory, gustatory, and visual areas, as well
as hypothalamus and amygdala.
According to Volkow et al. [8], the processing of emotion-
ally salient and behaviourally adaptive information may
be at the core of response-reinforcement relations. The
role of the frontal cortex, and specifically the anterior cin-
gulate gyrus (CG), in emotional processing has been dem-
onstrated in several imaging studies. Studies indicate an
important integrative role for the OFC and CG in the anal-
ysis of information that carries an emotive, evaluative and
in the long term, survival significance for an individual
[8].
Synaptic DA transmission
Seeman and Madras [9] suggested that methylphenidate
(MP) blocks the dopamine transporter (DAT), resulting in
increased extracellular DA, activating autoreceptors and
leading to an attenuation of DA release in response to
phasic DA firing. On the other hand, a second hypothesis
by Volkow et al suggests that the blocked DAT overcomes
the inhibitory effects for activation of the autoreceptors,
leading to a net effect of DA accumulation in the synapse,
with amplification of DA signals resulting from tonic as
well as phasic DA [8].
Grace has pointed out that by interfering with dopamine
re-uptake, stimulants allow dopamine to escape the syn-
aptic cleft, thereby depressing subsequent spike-depend-
ent phasic dopamine release by increasing the tonic
stimulation of the auto-receptor. Thus subcortical down-
regulation depends on presynaptic auto-inhibition
through autoreceptors [10,11]. This mechanism is similar
to that proposed by Seeman and Madras, who pointed out
that stimulants raise extracellular levels of dopamine sev-
eral-fold, but reduce the extent to which dopamine is
released with nerve impulses, compared with the impulse-
associated release in the absence of the drug. However at
higher doses, stimulants are found to produce generalised
stimulation of the nervous system, as a result of very high
concentrations of extracellular dopamine at rest, and
markedly increased release of dopamine with nerve
impulses overcoming presynaptic inhibition of dopamine
release [12].
Volkow et al. used positron emission tomography (PET)
to demonstrate that extracellular DA increases in propor-
tion to the level of DAT blockade, and the rate of DA
release by cell firing. The latter increases were found to be
greater when methylphenidate was given concomitantly
with a salient rather than a neutral stimulus. The authors
postulated that enhanced saliency and MP motivates the
improved school performance observed with methylphe-
nidate [8]. According to Volkow et al., symptoms of inat-
tention have been mainly linked with striatum and
cingulate gyrus, those of hyperactivity with striatum, and
those of impulsivity with nucleus accumbens, while
impairment in executive tasks is linked with the dorsola-
teral prefrontal cortex [13,14].
Dopamine and working memory
Goldman-Rakic  et al. investigated the pharmacological
actions of drugs on neurons as they are engaged in cogni-
tive processes in awake behaving animals [15]. They have
shown that the 'memory fields' of the prefrontal cortex are
modulated by neurotransmitters such as dopamine serot-
onin and gamma-amino-butyric acid (GABA) in different
ways [16-18]. Goldman-Rakic et al. showed that the spa-
tial tuning of prefrontal neurons engaged in spatial work-
ing memory was enhanced at moderate levels of
occupancy, and reduced at both lower and higher levels of
occupancy. The specificity of drug action on single cell
activity was thought accounted for by the specific synaptic
arrangement of D1 receptors in spines that receive excita-
tory inputs from visual pathways carrying highly proc-
essed visuo-spatial information. The model postulated an
optimal level of D1receptor occupancy for efficient physi-
ological signalling and optimal performance [15].
Spatial working memory has been associated with the
dorsolateral PFC, while the orbital and ventromedial PFC
allow recognition and inhibition of emotional responses,
important for appropriate social behaviour [19]. Gold-
man-Rakic and colleagues pointed out that a full under-Behavioral and Brain Functions 2008, 4:12 http://www.behavioralandbrainfunctions.com/content/4/1/12
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standing of the functional capacity of even a single
pyramidal cell requires knowledge not only of its biophys-
ical properties but its circuitry and signalling mechanisms
in vivo. Thus experimental depletion of dopamine in pre-
frontal areas of rhesus monkeys has been shown to pro-
duce impairments in working memory performance
[15,20]. Furthermore Goldman-Rakic et al. [21] and
Lidow  et al. [22] have showed that the D1  family of
dopamine receptors are at least 20-fold more abundant
than D2 family of receptors in the PFC. The D1 receptor
was also found to be in close proximity to putative gluta-
matergic axon terminals, giving rise asymmetric synapses
on the same spine.
Muly et al. also studied the distribution of D1 receptor in
GABAergic interneurons, and shown it is preferentially
found in those subtypes of interneurons which provide
the strongest inhibitory input to the perisomatic region of
cortical pyramidal cells [23]. They suggested a circuit
model to explain the biphasic action of D1 receptor stim-
ulation on working memory performance and neuronal
delay period firing, which focuses on the interactions
between pyramidal and non-pyramidal neurons. The
authors believe that D1 receptor stimulation enhances
excitatory transmission to both pyramidal cells and
interneurons, but the enhancement is more effective on
pyramidal cells, because of the closer contacts with
dopaminergic axon terminals. On pyramidal neurons, the
spine may act as a diffusion barrier, while on interneurons
D1 receptor synapses are located on the shaft allowing for
more diffusion of second messengers [24,25].
COMT and development
In humans, the catechol-O-methyltransferase (COMT)
gene contains a common variation in its coding sequence,
which translates valine (Val) to methionine (Met). At
room temperature the Met allele has one-fourth the
enzyme activity of the Val allele. It is believed that COMT
is important in the metabolism of DA in the prefrontal
cortex (PFC) whereas the dopamine transporter (DAT) is
more important in the striatum. The Val allele associated
with high -activity COMT increases phasic and reduces
tonic DA transmission sub-cortically and decreases DA
concentrations cortically. This leads to an increase in D2
and a decrease in D1 receptor transmission; as a result
there is decreased stability of neural networks, underlying
working memory representations. The Met allele associ-
ated with low-activity COMT decreases phasic and
increases tonic DA transmission sub-cortically, and
increases DA concentrations cortically: this is associated
with increased D1 and decreased D2 transmission in the
PFC [26]. This increases the stability of networks mediat-
ing sustained working memory representations. A recent
study found a small but significant relationship between
Val158Met genotype and executive function in healthy
individuals but not in schizophrenia [27]. Thus the
COMT gene (possibly in conjunction with other DA
genes) may help predict DA function in the PFC. How-
ever, genetic studies in ADHD have shown limited associ-
ation with ADHD [28]. This may be a developmental
issue related to the late development of cortical PFC con-
nections in adolescence, with late 'turning on' of the
COMT gene [29].
According to Lewis and Gonzalez-Burgos, dendritic spines
are the principal targets of excitatory synapses to pyrami-
dal neurons [30]. Excitatory connections from the medio-
dorsal thalamus, the principal source of inputs to the
dlPFC, synapse primarily on dendritic spines. Dendritic
spine density on dlFPC layer 3 pyramidal neurons under-
goes a substantial decline during adolescence in primates.
Activity-dependent strengthening and pruning appears to
underlie synapse stabilisation. It is suggested that func-
tionally immature synapses may not be able to provide
compensation for synaptic dysfunction prior to adoles-
cence, because they have a very low AMPA receptor contri-
bution, rendering them silent at the resting memory
potential, and a relatively high probality of glutamate
release, and thus subject to quick exhaustion of glutamate
pools after repetitive activation. It is likely that a range of
factors including labour-delivery, alcohol, nicotine and
other stressors may affect the development of dlPFC cir-
cuitry. Dopamine is thought to exert a modulating influ-
ence on the dlPFC. It is thought that prefrontal pyramidal
neurons may directly excite mesocortical DA neurons in
the ventral mesencephalon and indirectly inhibit mesotri-
atal DA cells through activation of GABAergic neurons in
mesencephalic cell nuclei [30]. Thus reduction in PFC cell
activity leads to an excess of DA receptor activation at sub-
cortical nuclei. In the primate dlPFC, D1 receptors are the
most abundant DA receptor subtype, and mediate most of
the cellular effects of DA in this subtype, and mediate
most of the cellular effects of DA in this region [31]. Thus
D1 receptors regulate sustained firing of dlPFC neurons
during the delay phase of delayed-response tasks that
require working memory [32,33]. DA neurons may also
have an important role in gating information loaded into
working memory buffers [34-37].
According to Lewis and Gonzalez-Burgos, COMT is
mostly an intracellular cystolic protein [38]. Therefore,
extracellular DA must be transported through the plasma
membrane before becoming a substrate of COMT enzy-
matic activity, raising the question of potential interaction
between genetic variants of COMT and the DA trans-
porter. However, because COMT expression levels in DA
neurons are relatively low [39,40], the availability of DA
to be inactivated by COMT is dependent on DA transport
through the membrane of cortical cells that express higher
levels of COMT (e.g. post-synaptic neurons or glia), andBehavioral and Brain Functions 2008, 4:12 http://www.behavioralandbrainfunctions.com/content/4/1/12
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that may express non-specific transporters with the ability
to uptake DA. It is thus important, according to the
authors, to note that COMT metabolises norepinephrine,
which heavily innervates the primate dlPFC [41] and
influences working memory function [42].
Lewis and Gonzalez-Burgos [30] point out that although
the interneuron depolarization and the increase in inhib-
itory currents produced by DA suggests net inhibitory
effects in the primate dlPFC, DA also changes the response
of pyramidal neurons to excitatory currents with a delayed
time course [32] and is consistent with other delayed D1
receptor-mediated effects [36]. This may partly account
for the inverted-U dose-response effect on dlPFC firing,
though these effects may be complex [43] Low levels of
DA receptor stimulation appear to selectively increase the
firing of neurons that are tuned to preferred stimuli during
tasks that require working memory [16].
Developmental hypothesis
While an association has been proposed between DRD1
and schizophrenia, most genetic association studies in
ADHD have been directed towards the dopamine trans-
porter, DAT1 and the DRD4 receptor. An influential
developmental hypothesis, the Dynamic Developmental
Theory (DDT) suggested that the dopaminergic system is
hypoactive in ADHD, and explains the behavioural
changes in terms of altered reinforcement and extinction
processes [44]. This leaves open the question of the role of
working memory in ADHD, presumably related to deficits
in the prefrontal DRD1 system. The present developmen-
tal hypothesis suggests early deficits in PFC connectivity,
in both young children and in ADHD. In this case stimu-
lant medications may 'remediate' a deficient working
memory system, as suggested in neuropsychological stud-
ies of vigilance [45,46].
Noradrenergic mechanisms
The above 'vigilance/working memory' hypothesis also
draws attention to the noradrenergic (NA) system. Opti-
mal prefrontal cortex function is thought to require opti-
mally functioning noradrenergic and dopaminergic input
to the prefrontal cortex [47,48]. A relatively recent
approach to the treatment of ADHD has been the finding
of beneficial effects from alpha-noradrenergic agents such
as atomoxetine and guanfacine. The molecular genetic
basis for the use of noradrenergic agents has been best
reviewed by Arnsten et al. [49]. They point out that it has
been appreciated for some time that dopamine (DA) is
necessary for proper prefrontal cortex (PFC) function, but
more recently a role for noradrenergic transmission has
been appreciated. According to Arnsten et al., the role of
the D1 receptor family in the regulation of PFC function
has received particular focus, particularly as D1 receptors
are found in high concentration in the PFC on dendritic
spines. This allows DA to modulate incoming informa-
tion to PFC pyramidal cells [50,51]. On the other hand,
supra-normal DA stimulation may impair PFC function,
providing an inverted-U effect. For example, Goldman-
Rakic et al., found that the D1 message and protein in the
cortex of rhesus monkeys was down-regulated by chronic
neuroleptic treatment, which both down-regulated D1
receptors and produced impairments in working memory
performance [23].
According to Arnsten et al. electrophysiological recordings
of PFC neurons in monkeys performing working memory
tasks, have shown that PFC neurons are able to hold
modality-specific information "on-line" over a delay
period and use this representational information to guide
behaviour in the absence of environmental cues. The
delay-related firing is thought to arise from feed-forward
microcircuits within the PFC, as cells with shared proper-
ties interconnect [52]. Arnsten et al. suggest there are no
drugs that distinguish between D1 and D5 receptors, and
moderate levels of D1/D5 receptor stimulation suppress
delay-related firing for non-preferred spatial directions,
and thus enhance spatial tuning. The authors point out
that while limited studies have been done in humans, due
to the lack of selective D1/D5 compounds available for
human use, studies with non-selective compounds sug-
gest that an "inverted-U" response may be evident in
humans as well as animals. They suggest that compounds
that prefer D1 receptors may be more helpful than D2 ago-
nists in improving verbal memory [52].
Alpha-2A receptor
According to Arnsten [53], relatively high doses of alpha-
2 agonists appear to have beneficial effects on cognitive
function, although these effects may be eroded by emerg-
ing sedative and hypotensive effects. However, Arnsten et
al. [52] and Arnsten and Leslie [54] have shown that the
ability of alpha-2 agonists to improve PFC function with-
out side effects was found to correspond with selectivity
for the alpha-2A receptor site. A comparison between the
three NA alpha-2 receptors guanfacine, clonidine and
BHT showed guanfacine had better selectivity than cloni-
dine, which is more selective than BHT 920. Thus open tri-
als [55-57] have shown beneficial effects of guanfacine,
including improved performance on the Continuous Per-
formance Task [58]. Arnsten suggests that NA-alpha-1 and
NA-alpha-2 receptors may have opposing effects in the
PFC, and that alpha-2 mechanisms may predominate
when basal NA release is moderate, as in normal attentive
wakening, and alpha-1 mechanisms may predominate
under conditions of stress with higher levels of NA release.
Thus alpha-2 agonists such as guanfacine may protect PFC
cognitive function during stress by preventing excessive
NA or DA release in the PFC [53].Behavioral and Brain Functions 2008, 4:12 http://www.behavioralandbrainfunctions.com/content/4/1/12
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Easton et al. utilised phMRI BOLD (magnetic resonance
imaging) contrast to image the blood oxygenation level
dependant response in rat brain regions following admin-
istration of guanfacine [59]. They postulated that activa-
tion of alpha-2 receptors in the dorsolateral PFC by an
agonist such as guanfacine might facilitate PFC neuronal
activity and in turn exert an inhibitory influence on other
cortical areas (such as premotor and motor areas) and/or
subcortical structures (such as the striatum) that are
involved in the control of locomotion. Time-course anal-
yses of saline vs guanfacine effects were carried out, using
both fixed and random effect analyses. Random effect
analysis showed that guanfacine produced positive BOLD
responses in frontal areas, including the frontal associa-
tion and secondary motor cortex and prelimbic region of
the PFC. This is consistent with single-photon emission
computed tomography (SPECT) evidence, which shows
improved cognitive performance and increased rCBF (cer-
ebral blood flow) values in the dorsolateral PFC following
guanfacine administration to young adult rhesus mon-
keys, and with human positron emission tomography
(PET) data showing increased regional cerebral blood
flow in frontal lobes following guanfacine administra-
tion. Positive BOLD changes also occurred in the dentate
gyrus and CA1. Guanfacine produced widespread negative
BOLD effects in the caudate, putamen, nucleus
accumbens and entorhinal cortex, suggesting decreased
dopaminergic neuronal function in this area.
Easton et al. interpreted their data as suggesting that guan-
facine acts on the prefrontal cortex (probably post-synap-
tically at alpha- 2 receptors) to increase cognitive and
associated functions, known to be dysfunctional in
ADHD sufferers, and also helps in the regulation of loco-
motor activity via inhibitory control of subcortical brain
regions, particularly the caudate putamen and nucleus
accumbens [59]. Thus guanfacine appeared to have the
ability to 'turn down' striatal activity, possibly of benefit
in the treatment of motoric hyperactivity. The investiga-
tors also demonstrated an intense positive BOLD effect in
the lateral hypothalamic area, which is strongly associated
with feeding behaviour, perhaps a basis of appetite or gas-
trointestinal side effects [60,61].
According to Easton et al. the alpha-2A adrenergic receptor
subtype appears to be the site of action of the beneficial
clinical effects of alpha-2A agonists on the prefrontal cor-
tex (PFC) [59]. While these receptors are localized both
pre- and post- synaptically, some lines of evidence are
thought to suggest that their site of action is post-synaptic
in the PFC [62]. Thus, guanfacine has been shown to dose-
dependently prevent deficits of spatial working memory,
suggesting a role in cognitive deficits associated with
NMDA receptor hypofunction [63,64]. Application of the
D1 receptor agonist SKF81297 has been shown to cause a
prominent increase of steady-state NMDA-evoked current
in acutely isolated PFC pyramidal neurons, and up-regu-
lation of NMDA receptor activity by dopamine D1 recep-
tors suggests reciprocal interactions between D1  and
NMDA receptors [65].
Arnsten et al. suggest that stimulants act to enhance the
release of and/or inhibit the reuptake of both DA and NE
(norepinephrine) [54]. Arnsten and Dudley [66] have
shown that the PFC-enhancing effects of methylphenidate
are prevented by blockade of either NE alpha-2 or DAD1
receptors, suggesting that stimulants facilitate endog-
enous stimulation of D1 and alpha-2A receptors in the
PFC. It is thought to increase delay-related firing and
strengthens the functional connectivity of microcircuits in
the PFC. In children, Scahill et al. found that immediate
release guanfacine was rated significantly better than pla-
cebo by teacher-rated ADHD (37% vs 8%) and subjects
performed significantly better on a Continuous Perform-
ance Test [67].
Arnsten et al. also suggest that as with DA, moderate levels
of NE are critical for proper PFC function [54]. They sug-
gest that the majority of alpha-2 receptors are localised
postsynaptically to NE terminals, and that blockade of
alpha-2 receptors in the PFC of monkeys erodes delay-
related cell-firing and recreates all the symptoms of
ADHD, with poor impulse control, impaired working
memory with underlying distractibility.
Wang et al. have shown that spatial working memory is
maintained by spatially tuned recurrent excitation within
networks of prefrontal cortical neurons [68]. They investi-
gated monkeys performing on an oculomotor spatial
delayed response, which required monkeys to make a
memory-guided saccade to a visuo-spatial target. Neurons
recorded from area 46 of the dorsolateral PFC were iso-
lated and subjected to iontophonetic application of phar-
macological agents. Intra-PFC administration of
guanfacine was shown to significantly enhance delay-
related activity for the 180° location (preferred direction)
in 28 out of 35 cases. Studies indicated that suppression
of cyclic AMP impaired WM performance.
Wang et al suggest that cAMP (cyclic AMP) has powerful
influences on Hyperpolarisation Activated Cyclic Nucle-
otide-gated (HCN) channels that pass on h current when
opened [68]. They are localised on distal pyramidal den-
drites and according to the authors, are co-expressed with
the alpha-2A adrenoreceptor, thus providing a potent sub-
stratum for functional integration in the primate PFC. In
electrophysiological studies with alpha-2A adrenorecep-
tor stimulation or cAMP inhibition, HCN channel block-
ade enhanced spatially tuned delay-related firing of PFC
neurons. Exposure to uncontrollable stress via excessiveBehavioral and Brain Functions 2008, 4:12 http://www.behavioralandbrainfunctions.com/content/4/1/12
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catecholamine release, high levels of D1 receptor stimula-
tion, or by activating cAMP, has been shown to impair
working memory. Under these conditions, the PFC is
functionally disconnected rendering it "decorticate". The
process may be exacerbated in patients with aberrant
genes that regulate cAMP signaling e.g. COMT [69]. This
co-localisation of cAMP, HCN channels and D1 excess
stimulation effects may help to explain the cross-talk
between DA and NE receptors in the PFC discussed below.
Vijayraghavan et al. showed that dopamine D1 receptor
stimulation in PFC produced an 'inverted-U' dose-
response, whereby either too little or too much D1 recep-
tor stimulation impaired spatial working memory [69].
This response has been observed across species, including
genetic linkages with human cognitive abilities, PFC acti-
vation states and DA synthesis. According to the authors
the cellular basis for the inverted U has long been sought,
with in vitro intracellular recordings supporting a variety
of potential mechanisms. Their study demonstrated that
the D1receptor agonist inverted-U response was observed
in PFC neurons of behaving monkeys: low levels of D1
receptor stimulation enhanced spatial tuning by suppress-
ing responses to non-preferred directions, whereas high
levels reduced delay-related firing for all directions, erod-
ing tuning. These actions of D1 receptor stimulation were
mediated in monkeys and rats by cyclic AMP intracellular
signaling. The evidence for an inverted-U at the cellular
level in behaving animals promised to bridge in vitro
molecular analyses with human cognitive experience.
Arnsten et al. have described three different subtypes of
alpha-2 adrenoreceptors in humans, the alpha-2A alpha-
2B and alpha-2C subtypes [54]. The alpha-2A and alpha-
2C subtypes are widely distributed in the brain, including
the PFC, the alpha-2B receptor is most concentrated in the
thalamus. Guanfacine is thought to be the most selective
agonist available for the alpha-2A subtype [70]. On the
other hand the sedating effects of clonidine are thought to
involve the thalamus, basal forebrain and other alpha-2B
and alpha-2C effects. Atomoxetine, which also has sedat-
ing effects in some children, may also have alpha-2B and/
or alpha-2C effects [48].
A recent study by Chamberlain et al. suggested that NE is
more sensitive in modulating lateral compared to orbital
PFC functioning [71]. They showed that atomoxetine (60
mg single dose) improved response inhibition on a stop-
signal task, but had no effect on a task requiring probabi-
listic learning. On the other hand administration of cita-
lopram (30 mg single dose) impaired probabilistic
learning with no effect on response inhibition. The
authors concluded that finding that atomoxetine
improved response inhibition in healthy volunteers
implicated ascending noradrenergic systems in its control,
whereas the role of 5-HT in probabilistic learning might
operate according to an inverted-U function.
Clinical implications
While clinical studies of guanfacine are limited, despite
some promising results, there has been considerable inter-
est in the use of atomoxetine. Despite some encouraging
trial results, [72] anecdotal clinical reports suggest limited
success in some children, and there have also be concerns
about suicidal ideation in a small number of patients [73].
This raises the question of the pharmacological actions of
atomoxetine, which also increases extrasynaptic levels of
NE and DA in the PFC.
The selectivity of atomoxetine for NE effects, was investi-
gated by Bymaster et al., utilising radioligands and micro-
dialysis studies [74]. They showed that atomoxetine
increased extracellular levels of NE in the prefrontal cortex
3-fold, but did not alter 5-HT levels. Atomoxetine also
increased DA concentrations in the PFC 3-fold but did not
alter DA in nucleus accumbens or striatum. In contrast
methylphenidate increased DA and NE equally in PFC,
but also increased DA in striatum and nucleus accumbens
to the same level. The authors suggest that atomoxetine is
thus less likely to have motoric or abuse liability.
Arnsten and Li suggest that noradrenergic transmission
has a vital beneficial effect on PFC function, particularly
via postsynaptic alpha-2-adrenoreceptors. Alpha -2 ago-
nists such as guanfacine have been shown to improve
working memory performance in monkeys after direct
infusion into the dorsolateral PFC [75]. Blockade of alpha
-2 receptors with yohimbine infusion was shown to
weaken working memory [76], and in addition to induce
motor hyperactivity [77]. Arnsten and Li have pointed out
that the PFC guides behaviour, thought and affect using
working memory, and that these processes are the basis of
executive functions, including regulation of attention,
planning and impulse control [75]. PFC function is
thought to be fundamental in ADHD [48,49]. As outlined
above, stimulation of the D1receptor within optimal lev-
els improves working memory performance, while higher
levels may erode performance [78,79]. The role of D2, D3
and D4 receptors in the PFC are, according to Arnsten and
Li less well understood, though it is of interest that NA has
high affinity for the D4 receptor, which may be considered
a catecholamine rather than a DA receptor [75].
Interestingly, while it has been accepted in the past that
the beneficial effect effects of stimulant medication were
mediated by DA transmission, Arnsten and Li suggest that
performance on PFC tasks in rats and mice on low oral
doses of methylphenidate may be mediated in part by the
alpha-2 adrenoreceptor [75]. Thus stimulants, atomoxet-
ine and guanfacine may exert therapeutic actions via D1Behavioral and Brain Functions 2008, 4:12 http://www.behavioralandbrainfunctions.com/content/4/1/12
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and alpha-2A receptor mechanisms, but under conditions
of stress, guanfacine may be more protective [80], given
that high doses of stimulants may impair cognition and
induce perseverative or restricted thinking [81].
Receptor specificity
Arnsten describes the PFC as using representational
knowledge, i.e. to guide overt responses as well as allow-
ing inhibition of inappropriate behaviours by gating the
processing of irrelevant stimuli. Studies in rats have
shown that low oral doses of methylphenidate that pro-
duce plasma drug levels similar to therapeutic doses in
humans, also improve PFC function, dependant on both
dopamine D1 and NE- alpha-2 receptor stimulation [82].
Acccording to Arnsten, the enhancing effects of alpha-2A
agonists are most likely mediated through G-mediated
suppression of CAMP intracellular signaling. Blocking
alpha-2 receptors in monkey PFC with yohimbine reduces
delay-related cell firing and impairs working memory, as
well as impulse control, recreating the profile of ADHD.
In contrast excessive stimulants produce cognitive inflexi-
bility through alpha 1, beta and high D1 stimulation [66].
It is still somewhat unclear whether DA effects in the PFC
are exerted primarily through the DAD1 receptor, or
alpha-2A receptor. Cornil et al have shown that dopamine
activates noradrenergic receptors in the quail preoptic area
[83]. They found that DA-induced inhibitions/excitations
were not blocked by selective dopaminergic receptor
antagonists, but were suppressed by selective alpha-
noradrenergic antagonists (yohimbine/prasozin). While
the mechanism of the cross-talk between DA and NE
receptors was unclear, the relatively similar structure of
DA and NE could potentially explain the binding of both
amines to the two receptor subtypes, as could co-localisa-
tion of cAMP, HCN channels and alpha-2A adrenorecep-
tor [68]. Studies of transgenic mice demonstrated that the
transporters for NE and DA lacked specificity, so that in
the prefrontal cortex, DA was mainly taken up by the NE
transporter [84]. The mechanisms and specificity in
human therapeutics remains an intriguing problem
whose solution offers more targeted understanding of
future treatments.
Conclusion
The above understandings have given rise to newer treat-
ment approaches. In particular there has been increased
interest in the efficacy of both non-stimulant and long-
acting agents. A variety of extended release dopaminergic
agents are being or have been produced by pharmaceuti-
cal companies but so far none have been selective for the
PFC alone, and may also be subject to motor and stereo-
typic effects at striatal level. Taken together the data seems
to suggest differences in specificity in the current medica-
tions used in the treatment of ADHD, with guanfacine
likely to be most specific for the treatment of attentional
deficits, while stimulants may have broader effects on
both vigilance and motor impulsivity depending on dose
levels. Atomoxetine has effects on attention, social affect,
anxiety and sedation via noradrenergic systems. Head to
head comparisons utilizing both vigilance and affective
measures, such as facial recognition may further elucidate
differential effects. At a theoretical level, the advent of spe-
cific noradrenergic therapies such as guanfacine, raises the
question of the role of working memory in the treatment
of ADHD. Also suggested, is a possible aetiological role of
developmental deficit or delay, at the prefrontal cortical
level, in ADHD.
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Abreviations
D1 Dopamine D1 receptor: PFC Prefrontal cortex; OFC
Orbitofrontal cortex;
DAT Dopamine transporter; COMT Catechol-O-methyl-
transferase;
NA Noradrenergic; NE Norepinephrine;
MRI Magnetic Resonance Imaging; BOLD Blood oxygen
level dependent;
SPECT Single-photon emission computed tomography;
NMDA N-methyl D-aspartate;
CAMP Cyclic AMP; HCN Hyperpolarisation Activated
Cyclic Nucleotide-gated
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